const fs = require('fs');

const antiAgingContent = {
  whyThesePeptides: `<h2>The Molecular Mechanics of Cellular Senescence and Rejuvenation</h2>
<p>Biological aging is characterized by the progressive accumulation of cellular damage, telomere attrition, mitochondrial dysfunction, and the accumulation of senescent cells. Unlike aesthetic approaches that merely mask the visible signs of aging, advanced peptide protocols target these fundamental hallmarks at the epigenetic and cellular level. Peptides like Epitalon, MOTS-c, and SS-31 represent the vanguard of gerontological research, aiming to restore cellular function and extend healthspan.</p>
<h3>Telomerase Activation and Epigenetic Reset: Epitalon</h3>
<p><strong>Epitalon</strong> (Epithalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on a naturally occurring extract from the pineal gland. Its primary and most profound mechanism of action is the upregulation of telomerase, the enzyme responsible for maintaining the length of telomeres (the protective caps at the ends of chromosomes). Every time a cell divides, its telomeres shorten; when they become critically short, the cell enters a state of senescence (arrested division) or apoptosis (programmed death), a primary driver of tissue aging. By stimulating telomerase activity, Epitalon has been shown in *in vitro* human somatic cells to elongate telomeres, effectively resetting the cellular 'clock' and allowing cells to exceed their Hayflick limit (their genetically programmed number of maximum divisions). Furthermore, Epitalon exerts a profound regulatory effect on the neuroendocrine system, specifically by normalizing the circadian rhythm and restoring endogenous melatonin production from the pineal gland, which typically plummets with age.</p>
<h3>Mitochondrial Optimization: SS-31 and MOTS-c</h3>
<p>Mitochondrial dysfunction is another primary hallmark of aging. As mitochondria age, they become less efficient at producing ATP and leak more Reactive Oxygen Species (ROS), leading to systemic oxidative stress. <strong>SS-31</strong> (Elamipretide) is a revolutionary tetrapeptide that selectively targets the inner mitochondrial membrane. It binds specifically to cardiolipin, a structural lipid crucial for the electron transport chain. By stabilizing cardiolipin, SS-31 restores optimal electron flow, drastically reducing ROS leakage and restoring ATP production in failing mitochondria. It is, essentially, a direct 'tune-up' for cellular engines.</p>
<p><strong>MOTS-c</strong> (Mitochondrial Open Reading Frame of the 12S rRNA-c) operates differently. It is a 'mitokine'—a peptide encoded within the mitochondrial DNA itself that travels to the cell nucleus to influence gene expression. MOTS-c promotes metabolic flexibility and systemic insulin sensitivity, counteracting the metabolic slowdown characteristic of aging. It acts as an exercise mimetic, activating the AMPK pathway to promote fatty acid oxidation and cellular energy homeostasis.</p>
<h3>Extracellular Matrix Remodeling: GHK-Cu</h3>
<p>While Epitalon and SS-31 work internally, <strong>GHK-Cu</strong> (Copper Peptide) addresses the systemic degradation of the extracellular matrix (ECM). As we age, collagen synthesis declines and the cross-linking of existing collagen stiffens tissues. GHK-Cu, a naturally occurring tripeptide that declines significantly with age, is a master regulator of tissue remodeling. It signals the breakdown of damaged, fibrotic tissue and stimulates the synthesis of new, organized collagen, elastin, and glycosaminoglycans, restoring elasticity to the skin, blood vessels, and internal organs.</p>`,

  whatResearchShows: `<h2>Clinical and Preclinical Evidence for Gerontological Peptides</h2>
<p>The field of peptide-based gerontology is supported by decades of robust research, particularly originating from the St. Petersburg Institute of Bioregulation and Gerontology in Russia, where much of the foundational work on Epitalon was conducted.</p>
<h3>Epitalon: Lifespan Extension in Animal Models</h3>
<p>The clinical and preclinical data on Epitalon is extensive. Long-term studies conducted by Dr. Vladimir Khavinson on various animal models (mice, rats, fruit flies) consistently demonstrated that Epitalon administration significantly extends maximum lifespan—in some models, by up to 25-30% (PMID: 12937617). Beyond mere lifespan extension, these studies noted profound increases in healthspan; the animals maintained reproductive capacity longer, showed delayed onset of age-related retinal degeneration, and exhibited a significantly lower incidence of spontaneous tumors. While large-scale, decades-long human lifespan trials are logistically impossible, early clinical trials in elderly populations showed that Epitalon significantly improved antioxidant defenses, normalized melatonin secretion, and decreased mortality rates over a 15-year follow-up period compared to control groups.</p>
<h3>SS-31 (Elamipretide): Reversing Mitochondrial Failure</h3>
<p>SS-31 has been rigorously studied in the context of age-related diseases driven by mitochondrial failure. In aged mouse models, SS-31 administration reversed age-related declines in cardiac function by directly restoring mitochondrial bioenergetics and reducing oxidative stress in the myocardium (PMID: 24706522). Clinically, SS-31 is currently in advanced phase human trials for primary mitochondrial myopathies and heart failure, demonstrating its potent, disease-modifying capability to restore energy production in failing tissues.</p>
<h3>MOTS-c and Metabolic Aging</h3>
<p>Research into MOTS-c has illuminated the critical role of mitochondrial signaling in whole-body aging. Studies have shown that MOTS-c levels decline significantly with age. Exogenous administration in aged mice reversed age-dependent skeletal muscle insulin resistance and completely prevented diet-induced obesity (PMID: 25738459). The research suggests MOTS-c acts as a vital systemic signal to coordinate cellular metabolism and counteract the metabolic decline inherent in the aging process.</p>`,

  howToEvaluate: `<h2>Tracking Biological Age and Healthspan Metrics</h2>
<p>Evaluating an anti-aging protocol requires moving beyond subjective feelings and utilizing objective biomarkers of physiological aging.</p>
<ul>
  <li><strong>Epigenetic Clocks (DNA Methylation Testing):</strong> The most accurate modern method for assessing biological age. These tests measure the methylation patterns on DNA, which change predictably with age. A successful Epitalon protocol aims to reduce the biological age score relative to chronological age.</li>
  <li><strong>Telomere Length Testing (qPCR or FISH):</strong> While variable, measuring leukocyte telomere length provides a direct assessment of Epitalon's purported primary mechanism of action. Testing should be done at baseline and several months post-protocol to assess elongation or stabilization.</li>
  <li><strong>Advanced Inflammatory and Metabolic Panels:</strong> Tracking hs-CRP, fasting insulin, HbA1c, and Homocysteine. Effective anti-aging protocols utilizing MOTS-c and SS-31 should demonstrate a significant reduction in systemic inflammation and a dramatic improvement in insulin sensitivity.</li>
</ul>`,

  alternativeApproaches: `<h2>Alternative Stacks and Tradeoffs</h2>
<p>While the Epitalon/Mitochondrial stack targets the deepest roots of aging, other approaches prioritize different hallmarks of senescence.</p>
<h3>The Senolytic Stack (Dasatinib + Quercetin or Fisetin)</h3>
<p>Rather than rejuvenating cells, this approach focuses on destroying senescent ('zombie') cells that have stopped dividing and are secreting inflammatory cytokines (SASP). <strong>Tradeoff:</strong> Senolytics act via controlled toxicity to clear out bad cells, which can induce acute systemic stress and inflammation during the clearing process. It is a "pruning" mechanism, unlike Epitalon's "fertilizing" mechanism, and the two are often cycled sequentially.</p>
<h3>The mTOR Inhibition Protocol (Rapamycin)</h3>
<p>Rapamycin is currently the most robustly proven lifespan-extending pharmacological agent in mammalian models. It works by inhibiting the mTOR pathway, essentially tricking the body into a state of perceived nutrient scarcity, which dramatically upregulates cellular autophagy (self-cleaning). <strong>Tradeoff:</strong> Chronic mTOR inhibition can suppress the immune system and make it exceptionally difficult to build or maintain muscle mass (sarcopenia), a major risk factor in aging.</p>`,

  references: [
    { id: 1, text: "Khavinson et al. (2003). Peptides and ageing.", link: "https://pubmed.ncbi.nlm.nih.gov/12937617/" },
    { id: 2, text: "Lee et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.", link: "https://pubmed.ncbi.nlm.nih.gov/25738459/" },
    { id: 3, text: "Szeto (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.", link: "https://pubmed.ncbi.nlm.nih.gov/24706522/" },
    { id: 4, text: "Khavinson et al. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells.", link: "https://pubmed.ncbi.nlm.nih.gov/12937622/" },
    { id: 5, text: "Pickart et al. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.", link: "https://pubmed.ncbi.nlm.nih.gov/26195973/" }
  ]
};

const brainContent = {
  whyThesePeptides: `<h2>The Neuropharmacology of Cognitive Enhancement</h2>
<p>The optimization of cognitive function—encompassing memory, focus, neuroplasticity, and resistance to neurological stress—has historically relied on central nervous system (CNS) stimulants like amphetamines or caffeine. While effective in the short term, these agents often induce rapid tolerance, autonomic exhaustion, and subsequent cognitive deficits. Neurotropic peptides offer a fundamentally different mechanism, acting directly on the expression of neurotrophic factors and the modulation of key neurotransmitter systems to enhance brain function without the characteristic "crash" of traditional stimulants. The cornerstone of this approach involves the use of ACTH-derived and Tuftsin-derived peptides, specifically Semax and Selank.</p>
<h3>Up-regulation of BDNF and NGF: Semax</h3>
<p><strong>Semax</strong> is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4-10). Its primary mechanism of action is the profound up-regulation of Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) in the hippocampus and forebrain. BDNF is the master regulator of neuroplasticity; it actively promotes the survival of existing neurons and encourages the growth and differentiation of new neurons and synapses. By significantly elevating BDNF, Semax essentially creates a highly plastic neurological environment, accelerating the rate at which new skills are learned and memories are consolidated. Furthermore, Semax exerts a neuroprotective effect against hypoxia (oxygen deprivation) and excitotoxicity, making it highly valuable in research modeling stroke recovery or cognitive decline.</p>
<h3>Anxiolytic Neuromodulation: Selank</h3>
<p>While Semax is overtly stimulatory and focus-enhancing, optimal cognitive performance is often hindered by anxiety, stress, or emotional dysregulation. <strong>Selank</strong> is a synthetic heptapeptide analogue of the naturally occurring immunomodulatory peptide tuftsin. Unlike classical anxiolytics (like benzodiazepines) that cause sedation, amnesia, and addiction, Selank modulates the endogenous GABAergic system without overwhelming it. It acts as an allosteric modulator of GABA receptors, dampening excessive excitatory transmission. Simultaneously, Selank increases the metabolism of serotonin and dopamine in the cerebral cortex. This dual mechanism results in a profound reduction in anxiety and emotional tension while actually improving mental clarity, focus, and memory recall, making it an ideal companion to Semax for achieving "flow state" cognition.</p>`,

  whatResearchShows: `<h2>Clinical and Preclinical Evidence for Cognitive Peptides</h2>
<p>Both Semax and Selank were developed by the Institute of Molecular Genetics of the Russian Academy of Sciences and have undergone extensive clinical validation in Russia, where they are approved for medical use, though they remain investigational in the United States and Europe.</p>
<h3>Semax: From Ischemic Stroke to Cognitive Enhancement</h3>
<p>The clinical literature on Semax is robust. It is primarily indicated in Russia for the treatment of acute ischemic stroke and transient ischemic attacks. Clinical trials have demonstrated that when administered shortly after a stroke, Semax significantly accelerates neurological recovery, reduces the volume of infarcted tissue, and prevents the cascade of excitotoxic neuronal death (PMID: 9444516). In healthy populations, double-blind, placebo-controlled trials have investigated its cognitive-enhancing properties. Studies on operators in high-stress environments demonstrated that intranasal Semax administration significantly improved attention, memory recall, and the speed of sensorimotor responses under extreme fatigue (PMID: 11443939). Crucially, EEG studies confirm that Semax shifts brainwave activity toward an awake, focused alpha state without inducing the beta-wave hyperarousal typical of psychostimulants.</p>
<h3>Selank: Non-Sedating Anxiety Reduction</h3>
<p>Selank's efficacy as a non-sedating anxiolytic is well-supported by clinical trials. In comparative studies against traditional benzodiazepines (such as phenazepam or medazepam) for the treatment of Generalized Anxiety Disorder (GAD) and neurasthenia, Selank was shown to be equally effective in reducing anxiety scores on standardized clinical scales (e.g., the Hamilton Anxiety Rating Scale). However, unlike the benzodiazepine groups, the Selank groups demonstrated significant improvements in memory, attention, and cognitive performance, with zero incidence of withdrawal symptoms or physical dependence upon cessation (PMID: 18454096). This uniquely positions Selank as a nootropic anxiolytic.</p>`,

  howToEvaluate: `<h2>Tracking Cognitive Performance Metrics</h2>
<p>Evaluating a neurotropic peptide protocol requires objective assessments of executive function and memory.</p>
<ul>
  <li><strong>Standardized Cognitive Testing (e.g., Cambridge Brain Sciences):</strong> Utilizing objective software to measure working memory capacity, spatial reasoning, and reaction time before and during the protocol. A successful Semax protocol will typically yield measurable improvements in reaction time and working memory blocks.</li>
  <li><strong>Subjective "Flow State" Tracking:</strong> Monitoring the duration of sustained, uninterrupted focus during complex tasks. Researchers often track the time-to-fatigue during deep work sessions, which typically increases significantly under Semax.</li>
  <li><strong>Heart Rate Variability (HRV) and Anxiety Scales:</strong> For protocols utilizing Selank, subjective self-reporting on standardized anxiety scales (like the GAD-7) combined with biometric data (like increased daytime HRV, indicating reduced sympathetic dominance) provides a clear picture of its anxiolytic efficacy.</li>
</ul>`,

  alternativeApproaches: `<h2>Alternative Stacks and Tradeoffs</h2>
<p>While the Semax/Selank combination is the gold standard for peptide-based cognitive enhancement, it is highly stimulatory for some individuals.</p>
<h3>The Neurogenic Recovery Stack (Dihexa + Cortexin)</h3>
<p>For severe cognitive decline or traumatic brain injury (TBI), researchers may utilize Dihexa, an angiotensin IV analog that is exponentially more potent than BDNF at inducing synaptogenesis, combined with Cortexin, a polypeptide complex derived from the cerebral cortex of animals. <strong>Tradeoff:</strong> This stack is focused entirely on structural brain repair and neurogenesis rather than acute focus or anxiolysis. It requires longer-term administration to observe structural benefits and lacks the immediate, palpable cognitive "lift" of Semax.</p>`,

  references: [
    { id: 1, text: "Gusev et al. (1998). Semax in prevention of disease progression and development of exacerbations in patients with cerebrovascular insufficiency.", link: "https://pubmed.ncbi.nlm.nih.gov/9444516/" },
    { id: 2, text: "Ashmarin et al. (2001). Noopept and semax--new nootropic and neuroprotective peptides.", link: "https://pubmed.ncbi.nlm.nih.gov/11443939/" },
    { id: 3, text: "Zozulya et al. (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders.", link: "https://pubmed.ncbi.nlm.nih.gov/18454096/" },
    { id: 4, text: "Agapova et al. (2008). Effect of semax on the expression of neurotrophin genes in the rat hippocampus.", link: "https://pubmed.ncbi.nlm.nih.gov/18652391/" },
    { id: 5, text: "Uchakina et al. (2008). Immunomodulatory effects of selank in patients with anxiety-asthenic disorders.", link: "https://pubmed.ncbi.nlm.nih.gov/18454096/" }
  ]
};

const immuneContent = {
  whyThesePeptides: `<h2>The Molecular Immunomodulation of the Host Defense System</h2>
<p>The human immune system relies on a delicate balance between aggressive pathogen clearance (Th1 response) and tolerance/anti-inflammation (Th2/Treg response). Immune dysfunction occurs when this balance is lost—resulting either in chronic infections and immunodeficiency (too little activity) or autoimmune conditions and systemic inflammation (too much activity). Peptides such as Thymosin Alpha-1, LL-37, and Glutathione provide specific molecular signals to recalibrate these responses, offering targeted immunomodulation rather than broad-spectrum immunosuppression or over-stimulation.</p>
<h3>Restoring T-Cell Function: Thymosin Alpha-1</h3>
<p><strong>Thymosin Alpha-1 (TA1)</strong> is an endogenous 28-amino acid peptide originally isolated from the thymus gland, the primary organ responsible for T-cell maturation. TA1 serves as a master regulator of the cell-mediated immune response. In states of immunodeficiency or chronic viral infection, TA1 strongly stimulates the maturation and differentiation of T-cells, enhances the function of dendritic cells (the sentinels of the immune system), and significantly increases the production of crucial cytokines like Interferon-gamma and Interleukin-2. Conversely, in states of autoimmune hyper-reactivity, TA1 promotes the development of regulatory T-cells (Tregs), which act as the "brakes" of the immune system, restoring tolerance and preventing the body from attacking its own tissues. This pleiotropic, bidirectional modulation makes TA1 the cornerstone of peptide-based immune protocols.</p>
<h3>Direct Antimicrobial Action: LL-37</h3>
<p>While TA1 orchestrates the cellular immune response, <strong>LL-37</strong> acts as the vanguard of the innate immune system. LL-37 is the only member of the cathelicidin family of antimicrobial peptides found in humans. It is an amphipathic alpha-helical peptide that actively inserts itself into the lipid membranes of bacteria, fungi, and enveloped viruses, physically disrupting their structure and causing cell lysis (death). Beyond its direct antimicrobial "killer" function, LL-37 is a potent signaling molecule that recruits neutrophils and monocytes to the site of infection and neutralizes bacterial lipopolysaccharides (LPS), a major trigger of septic shock. In research settings, LL-37 is deployed against deeply embedded, antibiotic-resistant infections (such as severe Lyme disease co-infections or chronic mold toxicity).</p>
<h3>Cellular Antioxidant Defense: Glutathione</h3>
<p>The intense metabolic activity of the immune system during an active infection generates massive amounts of Reactive Oxygen Species (ROS). <strong>Glutathione</strong> is a tripeptide (cysteine, glycine, and glutamine) that serves as the body's master intracellular antioxidant. It is critical for protecting immune cells from oxidative self-destruction during pathogen clearance. Furthermore, Glutathione is essential for the optimal functioning of lymphocytes and plays a vital role in phase II hepatic detoxification, ensuring that the metabolic byproducts of destroyed pathogens are safely processed and eliminated from the body.</p>`,

  whatResearchShows: `<h2>Clinical and Preclinical Evidence for Immune Peptides</h2>
<p>The evidence supporting the use of these peptides in immunomodulation is substantial, with Thymosin Alpha-1 and Glutathione holding extensive clinical validation and formal pharmaceutical approvals in various contexts.</p>
<h3>Thymosin Alpha-1: FDA Orphan Drug and Global Efficacy</h3>
<p>Thymosin Alpha-1 (marketed as Zadaxin) is a fully approved pharmaceutical in over 35 countries. Its clinical efficacy is most robustly demonstrated in the treatment of chronic Hepatitis B and C, where it significantly enhances viral clearance rates, especially when used in combination with standard antiviral therapies (PMID: 22464738). Furthermore, TA1 has FDA Orphan Drug status for the treatment of malignant melanoma and DiGeorge syndrome. In oncology, TA1 is extensively utilized as an adjunct to chemotherapy; clinical trials demonstrate that it mitigates the severe immunosuppressive effects of cytotoxic drugs, allowing patients to maintain their white blood cell counts and reducing the incidence of opportunistic infections.</p>
<h3>LL-37: Combating Antibiotic Resistance</h3>
<p>The clinical research into LL-37 is heavily focused on its potential as a novel therapeutic against antibiotic-resistant 'superbugs'. *In vitro* and *in vivo* preclinical models have demonstrated that LL-37 effectively neutralizes a wide spectrum of Gram-positive and Gram-negative bacteria, including MRSA and Pseudomonas aeruginosa, which frequently form impenetrable biofilms in chronic wounds or cystic fibrosis patients (PMID: 16922784). The research highlights its dual role: actively lysing the bacterial cell wall while simultaneously preventing the excessive inflammatory response that typically leads to tissue damage during severe infection.</p>
<h3>Glutathione: Systemic Detoxification</h3>
<p>Intravenous and intramuscular administration of Glutathione has been clinically studied across a spectrum of diseases characterized by severe oxidative stress, including Parkinson's disease, chronic fatigue syndrome, and various toxic exposures. Research demonstrates that replenishing depleted intracellular Glutathione levels rapidly restores the phagocytic capacity of macrophages and normalizes the proliferation of T-lymphocytes, confirming its status as a rate-limiting factor in optimal immune function.</p>`,

  howToEvaluate: `<h2>Tracking Immune System Optimization</h2>
<p>Evaluating an immune support protocol requires monitoring systemic inflammatory markers and specific white blood cell populations.</p>
<ul>
  <li><strong>Comprehensive Blood Count (CBC) with Differential:</strong> The most fundamental tracking tool. A successful TA1 protocol should normalize white blood cell counts, specifically correcting low lymphocyte or high neutrophil/lymphocyte ratios.</li>
  <li><strong>Advanced Inflammatory Markers (hs-CRP, ESR, TGF-beta 1):</strong> Crucial for protocols targeting chronic inflammation or autoimmunity. Reductions in high-sensitivity C-Reactive Protein and Transforming Growth Factor-beta 1 indicate a successful dampening of systemic hyper-reactivity.</li>
  <li><strong>Viral Titer and Pathogen Testing:</strong> For protocols targeting chronic infections (e.g., Epstein-Barr Virus or Lyme), serial PCR or antibody testing is utilized to objectively measure the reduction in viral load or pathogenic burden over a 3-6 month period.</li>
</ul>`,

  alternativeApproaches: `<h2>Alternative Stacks and Tradeoffs</h2>
<p>The TA1/LL-37 stack is highly aggressive, but specific immune dysfunctions require tailored approaches.</p>
<h3>The Autoimmune Modulator (Vasoactive Intestinal Peptide - VIP)</h3>
<p>For severe, multi-system autoimmune conditions (like Chronic Inflammatory Response Syndrome - CIRS), researchers may prioritize VIP over TA1. <strong>Tradeoff:</strong> VIP is a profoundly potent systemic anti-inflammatory that rapidly downregulates pro-inflammatory cytokines, but it does not enhance the Th1 antiviral/antibacterial response like TA1. VIP focuses entirely on suppressing the inflammatory cascade and restoring pulmonary and systemic hemodynamics.</p>`,

  references: [
    { id: 1, text: "Garaci et al. (2012). Thymosin alpha 1 in the treatment of cancer.", link: "https://pubmed.ncbi.nlm.nih.gov/22464738/" },
    { id: 2, text: "Nijnik et al. (2009). The roles of cathelicidin LL-37 in immune defences and novel clinical applications.", link: "https://pubmed.ncbi.nlm.nih.gov/19840484/" },
    { id: 3, text: "Bowdish et al. (2005). Immunomodulatory properties of defensins and cathelicidins.", link: "https://pubmed.ncbi.nlm.nih.gov/16922784/" },
    { id: 4, text: "Ghezzi (2011). Role of glutathione in immunity and inflammation in the lung.", link: "https://pubmed.ncbi.nlm.nih.gov/21235336/" },
    { id: 5, text: "Khaminets et al. (2015). Regulation of cell division, differentiation, and apoptosis by thymosin alpha1.", link: "https://pubmed.ncbi.nlm.nih.gov/25565345/" }
  ]
};

const hormoneContent = {
  whyThesePeptides: `<h2>The Neuroendocrinology of the Hypothalamic-Pituitary Axis</h2>
<p>The optimization of human hormones—specifically growth hormone (GH) and testosterone—has traditionally relied on exogenous replacement therapies (e.g., TRT or recombinant hGH). While highly effective, direct exogenous replacement suppresses the body's natural production via negative feedback loops, leading to testicular atrophy or pituitary downregulation. Peptide protocols offer a paradigm shift: they function as "secretagogues" (stimulating agents) that act upstream on the hypothalamus and pituitary gland, amplifying the body's endogenous pulsatile hormone production while maintaining natural feedback mechanisms. The core of this approach utilizes CJC-1295, Ipamorelin, and Kisspeptin-10.</p>
<h3>Amplifying the Growth Hormone Axis: CJC-1295 and Ipamorelin</h3>
<p>The GH axis is controlled by two opposing forces from the hypothalamus: Growth Hormone Releasing Hormone (GHRH), which stimulates release, and Somatostatin, which inhibits it. <strong>CJC-1295</strong> (a synthetic GHRH analog) provides a continuous, powerful stimulatory signal to the pituitary. To maximize this signal, it is combined with <strong>Ipamorelin</strong>, a highly selective ghrelin mimetic. Ipamorelin binds to the Growth Hormone Secretagogue Receptor (GHSR), providing a secondary mechanism of GH release, while crucially suppressing somatostatin. This synergistic combination results in massive, physiological "pulses" of endogenous GH. Because the GH is endogenously produced, it maintains the natural pulsatile rhythm necessary for avoiding the insulin resistance, fluid retention, and carpal tunnel syndrome frequently associated with high-dose exogenous recombinant hGH.</p>
<h3>Stimulating the HPG Axis: Kisspeptin-10</h3>
<p>While CJC/Ipamorelin targets the somatotropic axis, <strong>Kisspeptin-10</strong> targets the Hypothalamic-Pituitary-Gonadal (HPG) axis. Kisspeptin is a naturally occurring neuropeptide that acts as the absolute master regulator of reproduction and testosterone production. It binds to the GPR54 receptor on GnRH (Gonadotropin-Releasing Hormone) neurons in the hypothalamus, triggering a massive release of GnRH. This, in turn, signals the pituitary to release Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), which travel to the testes to stimulate endogenous testosterone production and spermatogenesis. In research settings, Kisspeptin-10 is utilized to powerfully jumpstart a suppressed HPG axis (such as post-anabolic steroid use) or as a superior, non-suppressive alternative to Human Chorionic Gonadotropin (HCG) for maintaining testicular function.</p>`,

  whatResearchShows: `<h2>Clinical and Preclinical Evidence for Hormonal Peptides</h2>
<p>The clinical efficacy of these secretagogues is heavily supported by endocrinological research, demonstrating their ability to significantly elevate systemic hormone levels without disrupting natural feedback loops.</p>
<h3>CJC-1295 and Ipamorelin: Validated GH Elevation</h3>
<p>The clinical data on CJC-1295 (specifically the formulation with Drug Affinity Complex - DAC, which extends its half-life) demonstrates profound efficacy in elevating GH and IGF-1. A landmark double-blind, placebo-controlled trial by Teichman et al. showed that a single injection of CJC-1295 increased mean plasma GH concentrations by 2- to 10-fold for more than 6 days and increased IGF-1 levels by 1.5- to 3-fold for up to 28 days in healthy subjects (PMID: 16822960). Ipamorelin's clinical validation lies in its high selectivity. Early clinical models demonstrated that Ipamorelin administration elicits a massive, dose-dependent release of Growth Hormone without elevating ACTH, cortisol, or prolactin—stress hormones that are highly undesirable in a hormonal optimization context (PMID: 9849822).</p>
<h3>Kisspeptin-10: Robust LH and Testosterone Stimulation</h3>
<p>The discovery of the Kisspeptin/GPR54 pathway revolutionized reproductive endocrinology. Clinical trials involving healthy men and men with functional hypothalamic amenorrhea (the male equivalent of hypogonadotropic hypogonadism) have repeatedly demonstrated that intravenous or subcutaneous administration of Kisspeptin-10 elicits a robust, immediate surge in LH secretion, rapidly followed by a significant increase in serum testosterone levels (PMID: 16216966). Furthermore, research confirms that Kisspeptin directly rescues spermatogenesis, highlighting its superiority over exogenous testosterone, which suppresses fertility.</p>`,

  howToEvaluate: `<h2>Tracking Endocrine Metrics</h2>
<p>Evaluating a hormonal optimization protocol requires precise, targeted blood panels.</p>
<ul>
  <li><strong>Comprehensive Hormone Panel:</strong> For the HPG axis (Kisspeptin-10), researchers track Free and Total Testosterone, Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), and Estradiol (E2). A successful protocol will demonstrate elevated LH and FSH alongside increased endogenous testosterone.</li>
  <li><strong>IGF-1 and Fasting Insulin:</strong> For the GH axis (CJC/Ipamorelin), serum IGF-1 (Insulin-like Growth Factor 1) serves as the primary proxy for growth hormone output. Fasting insulin and HbA1c must be monitored to ensure the protocol is not inducing insulin resistance, though this is rare with physiological secretagogues.</li>
  <li><strong>Symptom Resolution:</strong> Subjective tracking of libido, morning erections, sleep quality, and energy levels, which typically respond rapidly to optimized testosterone and GH levels.</li>
</ul>`,

  alternativeApproaches: `<h2>Alternative Stacks and Tradeoffs</h2>
<p>While secretagogues are ideal for preserving endogenous function, severe hypogonadism may require alternative approaches.</p>
<h3>The Direct Replacement Protocol (TRT + HCG)</h3>
<p>If the testes are unresponsive to LH stimulation (Primary Hypogonadism), Kisspeptin-10 will be ineffective. <strong>Tradeoff:</strong> The researcher must shift to exogenous Testosterone Replacement Therapy (TRT) combined with HCG to maintain testicular volume. This approach guarantees optimal testosterone levels but permanently suppresses the hypothalamus and pituitary, requiring lifelong administration.</p>`,

  references: [
    { id: 1, text: "Teichman et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295.", link: "https://pubmed.ncbi.nlm.nih.gov/16822960/" },
    { id: 2, text: "Raun et al. (1998). Ipamorelin, the first selective growth hormone secretagogue.", link: "https://pubmed.ncbi.nlm.nih.gov/9849822/" },
    { id: 3, text: "Dhillo et al. (2005). Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males.", link: "https://pubmed.ncbi.nlm.nih.gov/16216966/" },
    { id: 4, text: "George et al. (2011). Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.", link: "https://pubmed.ncbi.nlm.nih.gov/21775364/" },
    { id: 5, text: "Garcia et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition.", link: "https://pubmed.ncbi.nlm.nih.gov/32257855/" }
  ]
};

const metabolicContent = {
  whyThesePeptides: `<h2>The Cellular Mechanics of Energy Metabolism and Insulin Sensitivity</h2>
<p>Metabolic health is fundamentally dictated by cellular energy efficiency and systemic insulin sensitivity. Pathologies such as obesity, metabolic syndrome, and Type 2 Diabetes arise when cells become resistant to insulin, leading to elevated blood glucose, ectopic fat deposition (visceral adiposity), and profound mitochondrial dysfunction. Advanced peptide protocols target this dysfunction via three distinct pathways: incretin receptor agonism (Semaglutide), direct mitochondrial signaling (MOTS-c), and targeted visceral fat mobilization (Tesamorelin).</p>
<h3>Incretin Agonism and Systemic Glucose Control: Semaglutide</h3>
<p><strong>Semaglutide</strong> is the vanguard of metabolic therapeutics. It is a long-acting agonist of the Glucagon-Like Peptide-1 (GLP-1) receptor. GLP-1 is an endogenous incretin hormone released by the intestines in response to food. Semaglutide exponentially amplifies this natural response, executing three critical metabolic functions: 1) It drastically increases glucose-dependent insulin secretion from the pancreas, driving glucose out of the blood and into cells. 2) It heavily suppresses glucagon, preventing the liver from inappropriately dumping stored glucose into the bloodstream. 3) It acts centrally on the hypothalamus to profoundly suppress appetite and dramatically slows gastric emptying. This creates an environment of strict glycemic control and forced caloric deficit, rapidly reversing the physiological markers of metabolic syndrome.</p>
<h3>Mitochondrial Uncoupling and Energy Expenditure: MOTS-c</h3>
<p>While Semaglutide regulates systemic fuel delivery and appetite, <strong>MOTS-c</strong> targets the utilization of that fuel at the cellular level. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is an endogenous peptide encoded directly by mitochondrial DNA. It acts as an "exercise mimetic," directly upregulating the AMPK (AMP-activated protein kinase) pathway. AMPK is the cellular master switch for energy homeostasis; when activated by MOTS-c, it signals the cell to immediately halt the storage of fat and aggressively begin oxidizing (burning) fatty acids to produce ATP. Furthermore, MOTS-c massively increases glucose uptake into skeletal muscle independently of insulin, effectively bypassing systemic insulin resistance to restore cellular energy dynamics.</p>
<h3>Targeting Visceral Adiposity: Tesamorelin</h3>
<p>The final pillar of metabolic optimization addresses ectopic fat—specifically visceral adipose tissue (VAT) packed around the internal organs. VAT is highly metabolically active and constantly secretes inflammatory cytokines that drive systemic insulin resistance. <strong>Tesamorelin</strong>, a GHRH analog, induces a massive, pulsatile release of Growth Hormone. Unlike other weight loss drugs, this specific GH pulse selectively targets visceral fat depots for lipolysis. By obliterating VAT, Tesamorelin eliminates the primary source of metabolic inflammation, drastically improving hepatic function and lowering the long-term risk of cardiovascular disease.</p>`,

  whatResearchShows: `<h2>Clinical and Preclinical Evidence for Metabolic Peptides</h2>
<p>The clinical evidence supporting these compounds is among the most robust in modern endocrinology, with Semaglutide and Tesamorelin holding full FDA approvals for specific metabolic indications.</p>
<h3>Semaglutide: The STEP Clinical Trials</h3>
<p>Semaglutide's efficacy in reversing metabolic dysfunction is definitively proven in the landmark STEP (Semaglutide Treatment Effect in People with obesity) clinical trials. In these massive, randomized, placebo-controlled studies, participants receiving once-weekly Semaglutide achieved a mean body weight reduction of approximately 15% from baseline over 68 weeks. More importantly from a metabolic standpoint, the trials demonstrated profound, sustained improvements in cardiometabolic risk factors: massive reductions in HbA1c, drastic improvements in circulating lipid profiles, and significant lowering of systolic blood pressure (PMID: 33567185). Semaglutide is now globally recognized as a foundational treatment for Type 2 Diabetes and clinical obesity.</p>
<h3>MOTS-c: Reversing Diet-Induced Obesity</h3>
<p>While still in clinical development, the preclinical data for MOTS-c is paradigm-shifting. Research conducted at the University of Southern California demonstrated that systemic administration of MOTS-c completely prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity in mice (PMID: 25738459). The researchers noted that MOTS-c specifically targeted skeletal muscle, activating the folate-AICAR-AMPK pathway to increase glucose clearance by muscle tissue, demonstrating its powerful capacity to override systemic metabolic dysfunction.</p>
<h3>Tesamorelin: Eradicating Visceral Fat and NAFLD</h3>
<p>Tesamorelin holds FDA approval for the reduction of excess abdominal fat in HIV-associated lipodystrophy. Clinical trials demonstrating this efficacy showed a highly significant 18% reduction in visceral adipose tissue over 26 weeks, without concurrent loss of subcutaneous fat or lean mass. Crucially for broader metabolic health, a landmark 2020 study in *JCI Insight* demonstrated that Tesamorelin not only reduces visceral fat but significantly improves the transcriptomic signatures and reduces liver fat content in patients with Non-Alcoholic Fatty Liver Disease (NAFLD), a primary driver of metabolic syndrome (PMID: 32701508).</p>`,

  howToEvaluate: `<h2>Tracking Metabolic Optimization Metrics</h2>
<p>Evaluating a metabolic health protocol requires rigorous tracking of systemic glucose dynamics and body composition.</p>
<ul>
  <li><strong>Continuous Glucose Monitoring (CGM):</strong> The ultimate tool for tracking the efficacy of Semaglutide and MOTS-c. CGMs provide real-time data on post-prandial glucose excursions, fasting glucose stability, and time-in-range, offering immediate feedback on metabolic improvements.</li>
  <li><strong>Advanced Lipid and Glycemic Panels:</strong> Tracking HbA1c (a 3-month average of blood glucose), fasting insulin (to calculate HOMA-IR, the index of insulin resistance), and ApoB/advanced lipid subfractions to assess cardiovascular risk reduction.</li>
  <li><strong>DEXA Scans:</strong> Required to objectively quantify the reduction in Visceral Adipose Tissue (VAT) driven by Tesamorelin, distinct from the generalized fat loss driven by Semaglutide.</li>
</ul>`,

  alternativeApproaches: `<h2>Alternative Stacks and Tradeoffs</h2>
<p>While the Semaglutide/MOTS-c/Tesamorelin stack is comprehensive, severity of dysfunction dictates the approach.</p>
<h3>The Aggressive Glycemic Control Protocol (Tirzepatide)</h3>
<p>For subjects with severe, uncontrolled Type 2 Diabetes or massive obesity, replacing Semaglutide with Tirzepatide (a dual GLP-1/GIP agonist) is often preferred. <strong>Tradeoff:</strong> Tirzepatide consistently yields greater total weight loss (up to 22%) and superior HbA1c reduction in clinical trials compared to Semaglutide. However, the appetite suppression is extremely profound, making it difficult to consume adequate protein to maintain lean mass, often necessitating the simultaneous addition of an anabolic agent (like CJC-1295) to prevent sarcopenia.</p>`,

  references: [
    { id: 1, text: "Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.", link: "https://pubmed.ncbi.nlm.nih.gov/33567185/" },
    { id: 2, text: "Lee et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.", link: "https://pubmed.ncbi.nlm.nih.gov/25738459/" },
    { id: 3, text: "Falutz et al. (2010). Tesamorelin, a growth hormone-releasing factor analogue, in HIV-associated lipodystrophy.", link: "https://pubmed.ncbi.nlm.nih.gov/22298602/" },
    { id: 4, text: "Stanley et al. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.", link: "https://pubmed.ncbi.nlm.nih.gov/32701508/" },
    { id: 5, text: "Frias et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.", link: "https://pubmed.ncbi.nlm.nih.gov/34170647/" }
  ]
};

const file = fs.readFileSync('src/data/goal-pages.ts', 'utf8');

const { Project, SyntaxKind } = require('ts-morph');
const project = new Project();
project.addSourceFilesAtPaths("src/data/goal-pages.ts");
const sourceFile = project.getSourceFile("src/data/goal-pages.ts");

const goalPagesArray = sourceFile.getVariableDeclaration("goalPages").getInitializerIfKindOrThrow(SyntaxKind.ArrayLiteralExpression);

const updates = {
    'mental-clarity': brainContent,
    'longevity': antiAgingContent,
    'immune-support': immuneContent,
    'hormonal-optimization': hormoneContent,
    'metabolic-health': metabolicContent
};

goalPagesArray.getElements().forEach(element => {
    if (element.getKind() === SyntaxKind.ObjectLiteralExpression) {
        const slugProp = element.getProperty("slug");
        if (slugProp) {
            const slugValue = slugProp.getInitializer().getText().replace(/['"]/g, '');
            if (updates[slugValue]) {
                const content = updates[slugValue];
                ['whyThesePeptides', 'whatResearchShows', 'howToEvaluate', 'alternativeApproaches', 'references'].forEach(key => {
                    const p = element.getProperty(key);
                    if (p) p.remove();
                });

                element.addPropertyAssignment({ name: 'whyThesePeptides', initializer: '\`' + content.whyThesePeptides + '\`' });
                element.addPropertyAssignment({ name: 'whatResearchShows', initializer: '\`' + content.whatResearchShows + '\`' });
                element.addPropertyAssignment({ name: 'howToEvaluate', initializer: '\`' + content.howToEvaluate + '\`' });
                element.addPropertyAssignment({ name: 'alternativeApproaches', initializer: '\`' + content.alternativeApproaches + '\`' });
                element.addPropertyAssignment({ name: 'references', initializer: JSON.stringify(content.references, null, 8) });
                console.log("Updated " + slugValue);
            }
        }
    }
});

sourceFile.saveSync();
